Table 1.
Myogenic tone after addition of blockers; EC50-values and maximum relaxation for bradykinin in the presence of SNP (1 µM), NS309 (1 µM) and CyPPA (6 µM)
| Treatment | n | Myogenic tone Contraction (Nm−1) | U46619 (0.1 µM) Contraction (Nm−1) |
Bradykinin |
|
|---|---|---|---|---|---|
| EC50 (nM) | Maximum relaxation (%) | ||||
| Control | 8 | 0.28 ± 0.06 | 1.0 ± 0.1 | 3.1 ± 1.1 | 96.3 ± 2.9 |
| SNP | 7 | 0.31 ± 0.04 | 1.0 ± 0.1 | 2.2 ± 1.4 | 92.2 ± 2.8 |
| Control | 8 | 0.30 ± 0.04 | 1.0 ± 0.1 | 3.9 ± 1.2 | 95.7 ± 1.9 |
| NS309 | 8 | 0.26 ± 0.05 | 1.0 ± 0.1 | 0.4 ± 0.2* | 97.4 ± 1.1 |
| NS309/charybdotoxin | 8 | 0.38 ± 0.10 | 1.0 ± 0.1 | 0.3 ± 0.2* | 98.3 ± 1.1 |
| NS309/apamin | 8 | 0.48 ± 0.12 | 0.9 ± 0.1 | 3.8 ± 1.4 | 75.8 ± 9.4* |
| NS309/charybdotoxin/apamin | 8 | 0.55 ± 0.13 | 1.0 ± 0.1 | 3.7 ± 1.5 | 76.8 ± 7.5* |
| Control | 7 | 0.26 ± 0.07 | 1.0 ± 0.1 | 2.6 ± 0.5 | 95.4 ± 4.6 |
| CyPPA | 7 | 0.31 ± 0.06 | 0.9 ± 0.1 | 0.3 ± 0.2* | 95.1 ± 1.9 |
| CyPPA/apamin | 7 | 0.45 ± 0.09 | 1.0 ± 0.1 | 3.2 ± 1.4 | 81.8 ± 9.3 |
Mean ± SEM Student's t-test.
*
P < 0.05 from their respective controls.
CyPPA, cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4- yl]-amine; NS309, 6,7-dichloro-1H-indole-2,3-dione 3-oxime; SNP, sodium nitroprusside; U46619, 9,11-dideoxy-9a,11a-epoxymethanoprostaglandin F2α.